We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
QINLOCK (Tudorrose Consulting Pty Ltd)
Product name
QINLOCK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
123 working days (255)
Active ingredients
ripretinib
Registration type
NCE/NBE
Indication
QINLOCK (tablet) is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumours (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.